Aspire Biopharma Holdings, Inc.
ASBP
$8.87
-$0.38-4.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 122.18% | 560.47% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 122.18% | 560.47% | |||
| Cost of Revenue | 312.39% | 326.42% | |||
| Gross Profit | -618.97% | 680.00% | |||
| SG&A Expenses | 62.86% | -23.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 51.22% | -10.39% | |||
| Operating Income | -49.98% | 11.71% | |||
| Income Before Tax | 60.65% | 31.54% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 60.65% | 31.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 60.65% | 31.54% | |||
| EBIT | -49.98% | 11.71% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 94.06% | 62.78% | |||
| Normalized Basic EPS | 87.84% | 65.69% | |||
| EPS Diluted | 94.06% | 62.78% | |||
| Normalized Diluted EPS | 87.84% | 65.69% | |||
| Average Basic Shares Outstanding | 562.35% | 83.92% | |||
| Average Diluted Shares Outstanding | 562.35% | 83.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||